DOCSLIB.ORG

Gilead Sciences, Inc

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Gilead Sciences, Inc Q4 2019 Earnings Results February 4, 2020 Forward-looking Statements The projected financial results presented in the following slides represent management's estimates of Gilead’s future financial results. Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include: Gilead’s ability to achieve its anticipated full year 2020 financial results; Gilead’s ability to accelerate or sustain revenues for its antiviral and other programs; Gilead’s ability to realize the potential benefits of collaborations or licensing arrangements, including those with The Rockefeller University, Kyverna Therapeutics, Inc., Eisai Co., Ltd., Kiniksa Pharmaceuticals, Ltd. and Glympse Bio, Inc.; Gilead’s ability to initiate clinical trials in its currently anticipated timeframes; the risk that safety and efficacy data from clinical studies may not warrant further development of Gilead’s product candidates, including Yescarta in combination with mavrilimumab, 3BNC117, 10-1074, GS-6207 and product candidates evaluated for bridging fibrosis and compensated cirrhosis due to NASH; Gilead’s ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead’s ability to receive regulatory approvals in a timely manner or at all, for new and current products, including FDA and MHLW approvals for filgotinib for the treatment of RA and FDA and European Commission approvals of KTE-X19 for the treatment of mantle cell lymphoma; Gilead’s ability to successfully commercialize its products, including expansion in China; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products; a larger than anticipated shift in payer mix to more highly discounted payer segments; market share and price erosion caused by the introduction of generic versions of Gilead products; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; and other risks identified from time to time in Gilead’s reports filed with the U.S. Securities and Exchange Commission (the SEC). In addition, Gilead makes estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. Gilead bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. There may be other factors of which Gilead is not currently aware that may affect matters discussed in the forward-looking statements and may also cause actual results to differ significantly from these estimates. Further, results for the quarter and the year ended December 31, 2019 are not necessarily indicative of operating results for any future periods. Gilead directs readers to its press releases, Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 and other subsequent disclosure documents filed with the SEC. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. All forward-looking statements are based on information currently available to Gilead and Gilead assumes no obligation to update or supplement any such forward-looking statements other than as required by law. Any forward-looking statements speak only as of the date hereof or as of the dates indicated in the statements. This presentation includes U.S. GAAP and non-GAAP financial measures, a complete reconciliation between these two measures is available on the Company’s website at www.gilead.com within the investor section. Management believes this non-GAAP information is useful for investors, when considered in conjunction with Gilead’s GAAP financial information, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead’s operating results as reported under U.S. GAAP. Non-GAAP measures may be defined and calculated differently by other companies in the same industry. 2 Table of Contents Pages Key Highlights 4 - 8 Financial Performance 9 - 26 Durable Core Business 29 - 41 Three Pillars of Gilead’s 42 - 48 Next Existing Pipeline Opportunities Chapter Strategy to Drive Additional Growth 49 - 53 Appendix 54 - 58 3 Key Highlights 4 Q4 2019 Earnings Call Highlights • Key decisions made and new corporate strategy in place to drive Gilead’s next chapter • Solid financial performance with product sales of $22.1 billion for FY 2019 (2% YoY growth), at upper end of revised guidance • Durable HIV franchise delivering all-time high of $16.4 billion for FY 2019 (12% YoY growth) and $4.6 billion for Q4 2019 (9% QoQ growth) − Biktarvy® sales of $4.7 billion for FY 2019 (300% YoY growth) and $1.6 billion in Q4 2019 (25% QoQ growth) • Successful Descovy® for PrEP launch, ~27% of individuals on PrEP in the U.S. now on Descovy • Submitted filgotinib NDA for RA and launch preparations underway in the U.S., Europe and Japan • Dividend increase to $0.68 from $0.63 per share, effective Q1 2020 (fifth consecutive annual increase) • Additional $5.0 billion share repurchase authorization (in addition to $3.4 billion at year-end from prior authorization, $8.4 billion in total) • 2020 Financial Guidance - product sales of $21.8 - $22.2 billion and non-GAAP diluted EPS of $6.05 - $6.45 − Starting in 2020, Gilead will no longer regularly exclude stock-based compensation expense from its non-GAAP financial information − For comparability purposes, full year 2019 non-GAAP operating income and non-GAAP diluted earnings per share would have been $10.4 billion and $6.13, respectively, had stock-based compensation expense not been excluded 5 Key Decisions Have Laid the Foundation for Change Made Kite Expanded Established Completed New Defined New Separate Operating Galapagos External Innovation Leadership Corporate Company Partnership Group Team Strategy Mar Jul Sep Oct 2020Dec 2019 6 Diverse, Highly Experienced Leadership Team Daniel O’Day Andrew Dickinson Brett A. Pletcher Christi Shaw Johanna Mercier Executive Chairman and Chief Financial Officer Executive Vice President, Chief Executive Officer, Kite Chief Commercial Officer Chief Executive Officer Corporate Affairs and General Counsel Jyoti Mehra Merdad Parsey, Taiyin Yang, PhD William A. Lee, PhD Executive Vice President, MD, PhD Executive Vice President, Executive Vice President, Human Resources Chief Medical Officer Pharmaceutical Development Research and Manufacturing 7 Anticipated Milestones Through 2021 Axi-cel Axi-cel P3 2L DLBCL data Expected iNHL approval Filgotinib Axi-cel Expected RA approvals in U.S., Europe, Japan Expected 2L DLBCL submission Filgotinib Axi-cel P3 enrollment completion for CD P2 1L DLBCL data Axi-cel Filgotinib Capsid inhibitor P2 iNHL data MANTA/MANTA-RAy enrollment completion Expected HTE submission Capsid inhibitor GLPG-19721 GLPG-16902 P1 initiation for PrEP P2 OA data P3 IPF futility analysis data Filgotinib KTE-X19 KTE-X19 P3 UC data Expected MCL approval Expected aALL approval H1 2020 H2 2020 2021 HTE – heavily treatment-experienced. 1 Optionable partner program. 2 Optioned partner program. 8 Financial Performance 9 Financial Highlights: Q4 2019 in millions, except percentages and per share amounts Q4 2018 Q3 2019 Q4 2019 YoY Change QoQ Change Product Sales $5,681 $5,516 $5,796 2% 5% HIV1 4,065 4,202 4,577 13% 9% HCV 738 674 630 (15%) (7%) Yescarta 81 118 122 51% 3% Other Products2 797 522 467 (41%) (11%) Non-GAAP Costs and Expenses3 $3,228 $2,680 $3,567 11% 33% COGS4 1,257 759 1,406 12% 85% Product Gross Margin 78% 86% 76% R&D 939 954 1,029 10% 8% SG&A 1,032 967 1,132 10% 17% Operating Margin4 44% 52% 39% Effective Tax Rate 24% 22% 25% Non-GAAP Net Income3 $1,873 $2,224 $1,653 (12%) (26%) Non-GAAP Diluted EPS3 $1.44 $1.75 $1.30 (10%) (26%) Shares used in per share calculation-diluted 1,299 1,274 1,273 (2%) 0% 1 HIV includes Atripla, Biktarvy, Complera/Eviplera, Descovy, Emtriva, Genvoya, Odefsey, Stribild, revenue share Symtuza, Truvada, and Tybost. Revenue share Symtuza represents Gilead’s revenue from cobicistat (C), FTC and TAF in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen. 2 Other products include AmBisome, Cayston, Hepsera, Letairis, Ranexa, Vemlidy, Viread, and Zydelig. 3 Non-GAAP financial information excludes acquisition-related, up-front collaboration and licensing, stock-based compensation and other expenses, fair value adjustments of equity securities and discrete tax charges or benefits associated with changes in 4 10 tax related laws and guidelines. In Q4 2019 and Q4 2018, COGS include inventory write-downs of $500 million and $410 million, respectively, for slow moving and excess raw material and work in process inventory primarily due to lower long-term demand for our HCV products. Financial Highlights: Full Year in millions, except percentages and per share amounts 2018 2019 YoY Change Product Sales $21,677 $22,119 2% HIV1 14,627 16,438 12% HCV 3,686 2,936 (20%) Yescarta 264 456 73% Other Products2 3,100 2,289 (26%) Non-GAAP Costs and Expenses3 $10,716 $11,385 6% COGS4 3,590 3,539 (1%) Product Gross Margin 83% 84% R&D 3,518 3,770 7% SG&A 3,608 4,076 13% Operating Margin4 52% 49% Effective Tax Rate 20% 21% Non-GAAP Net Income3 $8,728 $8,466 (3%) Non-GAAP Diluted EPS3 $6.67 $6.63 (1%) Shares used in per share calculation-diluted 1,308 1,277 (2%) 1 HIV includes Atripla, Biktarvy, Complera/Eviplera, Descovy, Emtriva, Genvoya, Odefsey, Stribild, revenue share Symtuza, Truvada, and Tybost.
Load more

Recommended publications
  • What's New in Hiv? Highlights & New Data on Hiv Treatment a Presentation for Healthtrust Members June 18, 2021
    WHAT'S NEW IN HIV? HIGHLIGHTS & NEW DATA ON HIV TREATMENT A PRESENTATION FOR HEALTHTRUST MEMBERS JUNE 18, 2021 SHIVANI PATEL, PHARMD PGY-1 PHARMACY RESIDENT ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL NAVANEETH NARAYANAN, PHARMD, MPH, BCIDP CLINICAL ASSOCIATE PROFESSOR RUTGERS UNIVERSITY ERNEST MARIO SCHOOL OF PHARMACY CONFLICT OF INTEREST DISCLOSURE There are no relevant financial interest to disclose for myself or my spouse/partner within the last 12 months. The preceptor has a financial interest/arrangement, affiliation or relationship with Astellas and Merck that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. Note: This program may contain the mention of suppliers, brand products, services, or drugs presented in a case study or comparative format using evidence-based research. Such examples are intended for educational and informational purposes only and should not be perceived as an endorsement of any particular supplier, brand, product, service or drug. 1 2 3 LEARNING Identify new antiretroviral Describe a two-drug regimen Outline key counseling points agents and their role in the for treatment-naïve to a patient receiving new OBJECTIVES management of HIV/AIDS individuals and factors to antiretroviral agents related consider when selecting an to drug administration, initial regimen for an potential side effects, and individual. drug-drug interactions DRUG NAME ABBREVIATIONS Abbreviation Full Name Abbreviation Full Name Abbreviation Full Name 3TC Lamivudine DTG Dolutegravir
    [Show full text]
  • Antiretroviral Treatment Optimisation
    Fit for purpose Antiretroviral treatment optimisation HIV i-Base March 2020 ABOUT HIV i-BASE HIV i-Base is a London-based HIV treatment activist organisation. i-Base works in the United Kingdom and internationally to ensure that people living with HIV are actively engaged in their own treatment and medical care and are included in policy discussions about HIV treatment recommendations and access. www.i-base.info ABOUT FIT FOR PURPOSE i-Base’s annual Fit for Purpose summarises key developments in antiretroviral treatment optimisation for low- and middle-income countries. ABOUT HIV PIPELINE 2020: NEW DRUGS IN DEVELOPMENT i-Base produces an annual HIV pipeline review as a companion to Fit for Purpose. http://i-base.info/hiv-pipeline-report-march-2020 Contents Introduction . 3. Fit for purpose: antiretroviral treatment optimisation . 4 What does the World Health Organization recommend? 6 What we know and the evidence gaps 8 What is planned or ongoing? 26 What to watch out for at CROI 2020 and next steps 40 References 41 HIV pipeline 2020: new drugs in development . 52. Introduction: eight months since IAS 2019 53 Regulatory approvals and submissions 56 Compounds in development by class 58 Conclusion 71 References 73 Funded by Unitaid. HIV i-Base 107 The Maltings 169 Tower Bridge Road London SE1 3LJ Tel: +44 (0) 208 616 2210 www i-base info admin@i-base org uk An HTB South supplement ISSN 2046-9373 Design & typesetting: the earth is round, Cape Town, RSA 2 Fit for Purpose: Antiretroviral Treatment Optimisation – March 2020 Introduction HIV i-Base produces Fit for Purpose – a review of antiretroviral therapy (ART) optimisation – annually for distribution at the International AIDS Society (IAS) conferences, with updates to coincide with other key HIV meetings.
    [Show full text]
  • A Concise Review of Existing Therapies and Recent Advances in the Management of HIV Infection
    Int. J. Pharm. Sci. Rev. Res., 64(1), September - October 2020; Article No. 28, Pages: 153-158 ISSN 0976 – 044X Review Article A Concise Review of Existing Therapies and Recent Advances in the Management of HIV Infection Hina Lal, Tarun Kumar, Siddhartha Dutta*, Kishna Ram 1Senior Resident, Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Jodhpur-342005, Rajasthan, India. *Corresponding author’s E-mail: [email protected] Received: 14-06-2020; Revised: 18-08-2020; Accepted: 26-08-2020. DOI: 10.47583/ijpsrr.2020.v64i01.028 ABSTRACT Human immunodeficiency virus (HIV) is an RNA retrovirus capable of replicating its genome by the DNA dependent RNA polymerase (DdRp). The virus infects the lymphocytes with the help of viral glycoproteins like Gp 120 and Gp 41. The entry of virus leads to the release of viral RNA inside the host cell, which is further replicated, and assembly of virion particles leads to the release of viral particles that further infect the other host cells. Established therapies include those that inhibit the entry of virus in the host cell, those inhibiting the integrase activity, those acting as protease inhibitors and also we have Nucleoside Reverse Transcriptase Inhibitors (NRTIs) and Non-Nucleoside reverse transcriptase inhibitors (NNRTIs) with NRTIS being the competitive inhibitors of DdRp also show mitochondrial toxicity. Protease inhibitors are known for their adverse effect profile and several drug interactions due to their enzyme inhibitory property. The most effective approach in the management is the highly active antiretroviral therapy containing the combined use of drugs having varied mechanisms of action.
    [Show full text]
  • Novel Drugs and Their Combinations Used for Treating Aids
    NOVEL DRUGS AND THEIR COMBINATIONS USED FOR TREATING AIDS Mehnaz Showkat 1, Humaira Bilal2, Bilquees3, Nahida Tabassum*4. 1-3 Research Scholar, Department of Pharmaceutical Sciences (Pharmacology Division), University of Kashmir, Srinagar, J&K-India190006 4 Professor Pharmacology, Head Department of Pharmaceutical Sciences, Dean School of Applied Sciences and Technology, University of Kashmir, Srinagar, J&K-India190006 Email Id: *[email protected]; [email protected]; 1 Abstract Over past 35 years HIV/AIDS has emerged as a major global health problem across the globe. Although the Highly Active Antiretroviral Therapy (HAART) has significantly contributed to the suppression of viral load and has greatly prolonged the patient survival rate, issues such as complexity of the regimen, drug interactions, adverse effects, cross resistance between the drugs, still pose a hurdle to successful treatment. There is a persistent need of newer antiretroviral drugs (ARVs) with increased potency, improved pharmacokinetic profiles and improved activity against resistant HIV strains. Proper understanding of HIV life cycle and interaction of the virus with host cell factors has led to the development of newer and effective ARVs like, Ibalizumab, Fostemsavir, Doravirine etc. These drugs offer a number of advantages over traditional drugs and present a new choice for patients with drug resistant disease. Fixed Dose Combinations (FDC’s) of currently available drugs have proven beneficial by reducing risk of emergence of drug resistant strains, less risk of medication errors, better patient compliance, reduced cost of treatment and simplified drug supply management. Besides, drugs belonging to different classes are currently in different stages of clinical trials, thus broadening the future scope of treatment.
    [Show full text]
  • Research Toward a Cure March 17, 2021 Table 1
    Research Toward a Cure March 17, 2021 Table 1. Current Clinical Trials Trial Trial Registry Identifier(s) Sponsor(s) Phase Estimated End Date/Interim Results ADOPTIVE IMMUNOTHERAPY alloRESIST: Evaluate the safety, immunologic, and NCT04248192 Catherine Bollard, Children's Research Phase I April 2024 virologic responses of donor derived HIV-specific T- Institute cells in HIV+ individuals following allogeneic bone marrow transplantation HST-NEETs: HIV-1 specific T-cells for HIV-infected NCT03485963 Children's Research Institute Phase I December 2021 individuals ANTIBODIES VRC01 (analytical treatment interruption in AMP trial NCT04801758 HIV Vaccine Trials Network N/A June 2022 participants) 10-1074-LS + 3BNC117-LS in primary HIV infection NCT04319367 Imperial College London Phase II March 2025 (not yet open for enrollment) UB-421 (antibody inhibitor of HIV binding to CD4 NCT04404049 UBP Greater China (Shanghai) Co., Ltd Phase II June 2024 receptors) (not yet open for enrollment) UB-421 NCT03743376 United BioPharma Phase II December 2021 (closed to enrollment) vedolizumab (anti-α₄ β₇ integrin antibody) NCT03147859 Ottawa Hospital Research Institute Phase II December 2021 CROI 2019, Abstract 393, Webcast PGT121 + VRC07-523LS +/- PGDM1400 NCT03721510 International AIDS Vaccine Initiative Phase October 2022 I/IIa VRC01 (broadly neutralizing antibody) in infants NCT03208231 NIAID Phase I/II February 2021 (closed to enrollment) VRC01LS + 10-1074 (broadly neutralizing antibodies) NCT03707977 NIAID Phase I/II October 2021 in early-treated children 10-1074-LS + 3BNC117-LS (long-acting broadly NCT03554408 Rockefeller University Phase I June 2021 neutralizing antibodies) (closed to enrollment) 3BNC117 + 10-1074 (broadly neutralizing antibodies) NCT03571204 NIAID Phase I June 2021 Entries shaded in light grey include analytical treatment interruptions (ATIs); in some cases, ATIs are only initiated if certain outcomes are achieved.
    [Show full text]
  • Gilead Sciences Annual Report 2020
    Gilead Sciences Annual Report 2020 Form 10-K (NASDAQ:GILD) Published: February 25th, 2020 PDF generated by stocklight.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-19731 GILEAD SCIENCES, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 94-3047598 (State or Other Jurisdiction of Incorporation) (IRS Employer Identification No.) 333 Lakeside Drive, Foster City, California 94404 (Address of principal executive offices) (Zip Code) 650-574-3000 (Registrant’s Telephone Number, Including Area Code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value, $0.001 per share GILD The Nasdaq Global Select Market Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Y es x No ¨ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes¨ No x Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Investor Fact Sheet
    Confidential Draft April 29, 2021 3:55 PM AT A GLANCE 1Q21 FINANCIALS NASDAQ: GILD PRODUCT SALES DILUTED NON-GAAP EPS OPERATING CASH FLOW Founded: 1987 HQ: FOSTER CITY, CA $6.3B $2.08 $2.6B $~80B Market Cap (as of 4/28/2021) COMMERCIAL PORTFOLIO HIGHLIGHTS Human Immunodeficiency Virus (HIV) ~13,600 Treatment Prevention Employees Presence in >35 Countries across 6 Continents Oncology Emerging Viruses 3 Primary Disease Areas: VIRAL DISEASES Hepatitis C Virus Hepatitis B Virus (HCV) (HBV) INFLAMMATORY DISEASES ONCOLOGY ANALYST COVERAGE Argus, Atlantic Equities, Baird, Bank of America, Barclays, BMO, Cantor Fitzgerald, Citi, Cowen, Evercore ISI, Goldman Sachs, Guggenheim Securities, Jefferies, JPMorgan, Maxim Group, Mizuho, Morgan Stanley, Morningstar, Needham, Oppenheimer, Raymond James, RBC, Redburn, SVB Leerink, Truist, UBS, Wolfe PIPELINE PRODUCT CANDIDATES NDA/BLA/MAA filings, Clinical stage NMEs via in-licensing, and Breathrough Therapy 47 Clinical Stage Programs1 15 13 7 P3 and Registrational P2 trials acquisitions accounting for 23 programs Designations 1 Including in-licensed or acquired programs currently between phase 1 and NDA/BLA/MAA approval. Program count does not include potential opt-in partner programs. Viral Diseases Pipeline Phase 1 Phase 2 Phase 3 Filed 1 Emerging Veklury® (remdesivir injectable form) COVID-19 outpatient Viruses Remdesivir inhaled form (GS-5734) COVID-19 HIV LA HTE Phase 2/3 Lenacapavir capsid inhibitor (GS-6207) HIV LA VS bNAb combination (GS-5423, GS-2872)2 HIV Cure Lefitolimod TLR-9 agonist (GS-1703)2 HIV Cure HIV Vesatolimod TLR-7 agonist (GS-9620) HIV Cure Elipovimab bNAb (GS-9722) HIV Cure Unboosted protease inhibitor (GS-1156) HIV Treatment Long acting bictegravir (GS-9883) HIV LA Hepcludex® (bulevirtide)4 HDV Hepcludex® (bulevirtide) + PEG-INF HDV HBV & HDV Selgantolimod TLR-8 agonist (GS-9688) HBV Cure Oral PD-L1 small molecule (GS-4224) HBV Cure 1Removed from pipeline 12Apr21 2Non-Gilead sponsored trial(s) ongoing.
    [Show full text]
  • Lääkeaineiden Yleisnimet (INN-Nimet) 31.12.2019
    Lääkealan turvallisuus- ja kehittämiskeskus Säkerhets- och utvecklingscentret för läkemedelsområdet Finnish Medicines Agency Lääkeaineiden yleisnimet (INN-nimet) 31.12.
    [Show full text]
  • Published by HIV I-Base Htb Supplement: 2020 Vol 21:(1) New
    ISSN 1472-4863 HIV pipeline2020-lite New drugs in development htb supplement: 2020 Vol 21:(1) C O N T E N T S Targets in the HIV lifecycle HIV pipeline 2020: targets in the HIV lifecycle 1 HIV attaches to a CD4 cell. 2 HIV enters a CD4 cell and HIV proteins and enzymes Entry inhibitors 1 HIV Monoclonal antibodies (mAb) are released into the cell. gp120 3 combinectin capsid Reverse transcriptase (RT) (GSK3732394) gp41 UB-421 (CD4 receptor) makes double strand HIV. 4 VRC01/LS and VRC07/LS Integrase enables HIV to CD4 receptor 3BNC117/LS and10-1074/LS join the cell DNA. CCR5 coreceptor 5 PGDM1400, 10E8.4/iMab Protease cuts and 6 reassembles new HIV. NRTIs/NRTTIs 2 PGT121 and elipovimab (GS-9722) (nukes) Final stages include N6LS (gp120) maturation and budding islatravir (EFdA) leronlimab PRO-140 (CCR5) as each cell produces MK-8504, MK-8583 hundreds of new virions. HIV RNA CD4 cell NNRTIs Rev inhibitor (non-nukes) 3 Cell nucleus elsulfavirine ABX-464 HIV DNA Protease cuts new viral material Capsid inhibitors 4 5 GS-6207 Integration GSK (pre-clinical) INIs (INSTIs) Maturation cabotegravir LA inhibitors 6 Maturation GSK’254 (oral) and budding GSK ’937 (LA) i-base.info (2020) HIV i-Base. March 2020 (www.i-Base.info) New HIV HIV pipeline 2020 update: new drugs in development 2 Maturation inhibitors 9 Introduction: eight months since IAS 2019 2 • GSK3640254 Regulatory approvals and submissions 2 Other compounds 9 Compounds in development by class 3 • elsulfavirine/VM-1500A Integrase inhibitors 3 • combinectin (GSK3732394) - adnectin/fusion inhibitor • cabotegravir LA • ABX464 NRTIs 3 • BIT225 • islatravir (EFdA) Development stopped or on hold 10 • MK-8504 and MK-8583 • GS-9131 - NRTI • GSK NRTTI • GS-PI1 - protease inhibitor bNAbs 5 Conclusion 10 • leronlimab (PRO140) References 11 • UB-421 i-Base publications 1 2 • VRC01 and VRC01LS ..................................................................
    [Show full text]
  • Älter Werden
    Schwerpunkt-Thema: Älter werden Rundbrief Sommer 2020 1Lübecker AIDS-Hilfe e.V. Editorial Aus der LAH Liebe Freundinnen und Freunde Wir bau(t)en um der Lübecker AIDS-Hilfe, Kurz nach Redaktionsschluss haben die Bauarbeiten begonnen. Eigentlich müsste ich aktuell grammatikalisch richtig schreiben: Kurz nach Redaktionsschluss werden die Bauarbeiten begonnen Corona hat uns alle im Griff … natürlich hatten auch wir überlegt, für unsere Sommer-Ausgabe das haben … denn noch sitze ich ja im Büro und kann diesen Artikel schreiben. Thema mit aufzunehmen, vielleicht sogar als Schwerpunkt. Am kommenden Montag wird es also losgehen, ßer-Schulungsraum-Begrüßungs-Frühstück”, das Da uns aber von allen Seiten Klar hat Corona auch Aus- Vor wenigen Tagen ist die Mai/ wenn der Rundbrief erscheint, sollen die Bauar- wissen wir erst kurz vorher. Natürlich werden wir Informationen über Corona wirkungen auf unsere Arbeit, Juni-Ausgabe von Projekt In- beiten beendet sein. euch dann entsprechend per Mail Informieren. – drücken wir es mal freund- ständig müssen wir unser formation erschienen. Unauf- Katjana und Hartmut werden dann im neuen Aktuell sieht es so aus, als wenn wir es anbie- lich aus – angeboten werden, Hygienekonzept den Vorgaben geregt, sachlich, ehrlich berich- Bürogewand sitzen und unser Schulungsraum ten werden können, merkt euch den Termin also haben wir uns entschlossen, entsprechend anpassen und tet Siegie Schwarze über den wird hell und groß sein. schon mal gerne vor. diesen Rundbrief „Corona-frei” das alles hat Auswirkungen aktuellen Stand von Corona. Wenn alles klappt, werden wir an dieser Stelle erscheinen zu lassen. Nun ja, auf unsere Veranstaltungs- Da wir es auch nicht besser auch noch ein Foto vom neuen Raum haben, Wir freuen uns auf jeden Fall auf unsere umge- fast … planung.
    [Show full text]
  • H1 & Q2 2020 Earnings Results
    H1 & Q2 2020 Earnings Results July 30, 2020 Forward-Looking Statements The projected financial results presented in the following slides represent management’s estimates of Gilead’s future financial results. Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include: the risks and uncertainties related to the impact of the COVID-19 pandemic on Gilead’s business, financial condition and results of operations; the risks and uncertainties related to the development and distribution of remdesivir as a treatment for COVID-19, including the possibility that FDA and other regulatory authorities may not approve remdesivir as a treatment for COVID-19, Gilead may never successfully commercialize remdesivir and Gilead may be unable to recoup the expenses incurred to date and future expenses related to the development and production of remdesivir; the risk that Gilead may be unable to sufficiently scale up the production of remdesivir in the currently anticipated timelines and unable to meet future supply needs; Gilead’s ability to achieve its anticipated full year 2020 financial results, including as a result of potential adverse revenue impacts from COVID-19 or increases in expenses due to the development and commercialization of remdesivir;
    [Show full text]
  • JP Morgan Healthcare Conference Daniel O’Day Chairman and Chief Executive Officer
    JP Morgan Healthcare Conference Daniel O’Day Chairman and Chief Executive Officer J a n u a r y 1 1 th, 2 0 2 1 Forward-Looking Statements Statements included in this presentation that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward- looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include: the risks and uncertainties related to the impact of the COVID-19 pandemic on Gilead’s business, financial condition and results of operations; the risks and uncertainties related to the development, manufacturing and distribution of Veklury as a treatment for COVID-19, including the uncertainty of the amount and timing of future Veklury revenues and the risk that Gilead may be unable to recoup the expenses incurred to date and future expenses related to the development and production of Veklury and Gilead may be unable to effectively manage the global supply and distribution of Veklury; Gilead’s ability to achieve its anticipated full year 2020 financial results, including as a result of potential adverse revenue impacts from COVID-19, increases in R&D expenses and potential revenues from Veklury; Gilead’s ability to make progress on and achieve its 2021 strategic business development and capital allocation goals; Gilead’s ability to make progress on any of its long-term ambitions laid out in its corporate strategy; Gilead’s ability
    [Show full text]